66 studies found for:    Paraneoplastic Syndromes
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Immunotherapy of the Paraneoplastic Syndromes
Condition: Paraneoplastic Syndromes
Intervention: Drug: Tacrolimus (FK506)
2 Completed Studies of Neurological Paraneoplastic Syndromes
Condition: Paraneoplastic Neurologic Degenerations (PNDs)
Intervention:
3 Recruiting The Study of Immune Cell (T Cell) Activity in Patients With Paraneoplastic Neurologic Syndromes
Condition: Paraneoplastic Syndromes
Intervention:
4 Unknown  Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalasia
Condition: Hypophosphatemia
Intervention:
5 Recruiting Study of Cytokines in Children With Opsoclonus-Myoclonus Syndrome
Condition: Opsoclonus-myoclonus Syndrome
Intervention:
6 Active, not recruiting MC-5A for Chemotherapy Induced Peripheral Neuropathy
Condition: Neuropathy, Paraneoplastic
Interventions: Device: MC-5A;   Drug: Sham device
7 Recruiting 3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)
Conditions: Lambert-Eaton Myasthenic Syndrome;   Congenital Myasthenic Syndrome
Interventions: Drug: 3,4-DIAMINOPYRIDINE;   Drug: 3,4-Diaminopyridine
8 Recruiting Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)
Conditions: Opsoclonus Myoclonus Syndrome;   Neuroblastoma
Interventions: Drug: Dexamethasone acetate;   Drug: dexamethasone and cyclophosphamide;   Drug: dexamethasone and rituximab
9 Available Expanded Access Study of Amifampridine Phosphate in LEMS, Congenital Myasthenic Syndrome, or Downbeat Nystagmus Patients
Conditions: Lambert-Eaton Myasthenic Syndrome;   Congenital Myasthenic Syndrome;   Downbeat Nystagmus
Intervention: Drug: Amifampridine Phosphate
10 Completed Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes
Condition: Congenital Myasthenic Syndrome
Intervention: Drug: Albuterol
11 Available Treatment of Lambert-Eaton Syndrome With 3,4 DAP
Condition: Lambert Eaton Myasthenic Syndrome
Intervention: Drug: 3, 4 DAP
12 No longer available Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP
Condition: Lambert Eaton Myasthenic Syndrome (LEMS)
Intervention: Drug: 3,4-diaminopyridine
13 Active, not recruiting Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome
Conditions: Lambert-Eaton Myasthenic Syndrome;   Eaton-Lambert Myasthenic Syndrome
Interventions: Drug: 3,4-DAP;   Drug: 3,4-DAP Taper to Placebo
14 Unknown  Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine
Condition: Lambert-Eaton Myasthenic Syndrome
Intervention: Drug: 3,4 diaminopyridine
15 Available Treatment Use of 3,4-Diaminopyridine
Conditions: Lambert Eaton Myasthenic Syndrome (LEMS);   Myasthenic Syndromes, Congenital
Intervention: Drug: 3,4-diaminopyridine
16 Available Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome
Condition: Lambert Eaton Myasthenic Syndrome
Intervention: Drug: 3, 4-Diaminopyridine
17 Available Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome
Condition: Lambert-Eaton Myasthenic Syndrome
Intervention: Drug: 3,4 DAP
18 Available 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)
Conditions: Lambert-Eaton Myasthenic Syndrome (LEMS);   Congenital Myasthenia (CM)
Intervention: Drug: 3,4-diaminopyridine
19 Completed Pregnancy Outcomes in Congenital Myasthenie Syndrome
Condition: Congenital Myasthenic Syndrome
Intervention:
20 Recruiting A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
Condition: Lambert Eaton Myasthenic Syndrome
Interventions: Drug: Amifampridine Phosphate;   Drug: Placebo

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years